Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 02:40pm CEST
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
07:18a EQS-ADHOC : AEVIS VICTORIA - Publikation Halbjahresbericht 2016
07:18a EQS-ADHOC : AEVIS VICTORIA - Publication of half-year report 2016
07:18a SCHRODERS : *goldman raises schroders price target to 3,000 (2,930) pence - 'neutral'
07:18a EQS-ADHOC : AEVIS VICTORIA - Publication du Rapport Semestriel 2016
07:18a SHAWBROOK : *goldman raises shawbrook price target to 275 (240) pence - 'neutral'
07:17a BURBERRY : *goldman raises burberry group price target to 1 ,480 (1,310) pence - 'neutral'
07:17a ROYAL BANK OF SCOTLAND : *goldman cuts rbs price target to 230 (240) pence - 'buy'
07:16a CYBG : *goldman initiates cybg with 'neutral' - target 245 pence
07:16a METRO BANK : *goldman cuts metro bank to 'sell' ('neutral') - target 2,050 (1,630) pence
07:16a NADL - North Atlantic Drilling Receives Notice of Early Contract Cancellation for the West Epsilon
Latest news
Advertisement
Hot News 
0.33%Asian Shares Down on Europe Financial Health Concerns
-0.10%EUR/GBP TECHNICAL ANALYSIS : Double Top May Be Taking Shape
-0.16%Gold Prices Await Fed Guidance, Crude Oil Eyes OPEC Meeting
Most Read News
09/26 Disney, Microsoft among possible Twitter suitors
09/26 WELLS FARGO : U.S. Labor Department launches review of all Wells Fargo complaints
09/26 VERIZON COMMUNICATIONS : U.S. senator seeks SEC probe of Yahoo disclosure on hacking
09/26 AmEx can bar merchants from steering card customers elsewhere
09/26 UPRISING ACTIVISTS : Charlotte mayor, police chief should resign
Most recommended articles
09/26Predicting the U.S. Elections With The WMA Trump/Clinton Barometer
01:15aDJSIEMENS : U.S. Firms Turn to German Training Model to Fill Jobs Gap
12:45a ARENA REIT (ASX : ARF) talks FY16 results and outlook
12:29a LOTTE CHEMICAL : South Korean court to hear arrest request for Lotte chairman on September 28
12:20aDJOil Prices Lower on Iran Comments, U.S. Crude Stocks Growth